By Budi Oetomo Narendra 
A groundbreaking study involving the long-term observation of chronic blood cancers has unveiled significant genetic distinctions between patients whose conditions remain stable for years and those whose diseases eventually escalate to more severe forms. These pivotal findings suggest that specific DNA alterations could revolutionize how clinicians diagnose, monitor, and assess treatment efficacy for these complex conditions, potentially identifying signs of progression years before overt symptoms manifest. The research also challenges existing diagnostic paradigms for a subset of patients, proposing that some current diagnoses may reflect normal aging processes rather than true blood cancers.
Decades of Data Illuminate Cancer Evolution
Published in the esteemed journal Cancer Discovery and concurrently presented at the American Association of Cancer Research (AACR) Conference in San Diego, the study was spearheaded by researchers at the Wellcome Sanger Institute in collaboration with numerous partners. The team meticulously integrated advanced genetic analysis with comprehensive clinical records, providing an unprecedented, multi-decade view into the evolutionary trajectory of chronic blood cancers. This deep dive into patient data spanning up to 25 years offers a critical understanding of disease development, shedding light on the molecular underpinnings of progression and stability.
Myeloproliferative neoplasms (MPNs) represent a group of rare, long-lasting blood cancers that originate in the bone marrow, the vital tissue responsible for producing all blood cells. In individuals affected by MPNs, the bone marrow produces certain blood cell types in an uncontrolled and excessive manner. This dysregulation can lead to a range of complications, from increased risk of blood clots and bleeding to the development of more aggressive conditions. The three main types of classic MPNs include Polycythemia Vera (PV), characterized by an overproduction of red blood cells; Essential Thrombocythemia (ET), marked by an excess of platelets; and Primary Myelofibrosis (PMF), which involves the build-up of scar tissue in the bone marrow, impairing its function.
The prevalence of MPNs, though rare, affects a substantial population. Approximately 40,000 individuals in the United Kingdom are currently living with an MPN, with around 4,000 new diagnoses made each year. These cancers are notorious for their slow, insidious progression, often beginning with somatic mutations – changes in DNA that are not inherited but acquired during a person’s lifetime – arising very early in life. These initial mutations are then compounded by additional genetic alterations that accumulate over several decades, contributing to the disease’s gradual evolution.
A cornerstone of MPN diagnosis traditionally relies on identifying mutations in specific genes, primarily JAK2, CALR, or MPL. These mutations are present in the vast majority of MPN patients and are crucial for confirming the diagnosis and guiding treatment decisions. However, a significant minority—around 10 percent of patients—do not exhibit any of these common genetic changes. In these challenging cases, diagnosis has historically been based largely on the morphological appearance of cells within the bone marrow, often leading to uncertainty. Consequently, some patients in this category might undergo cancer treatments, including chemotherapy, without definitive genetic evidence to confirm an underlying blood cancer, raising questions about the appropriateness and necessity of such interventions.
Unraveling the Mystery of Disease Progression
The clinical course of chronic blood cancer exhibits considerable variability among patients. Some individuals experience long periods of stability, requiring only minimal treatment and maintaining a good quality of life for many years. In stark contrast, others eventually face a deterioration of their condition, progressing to more severe and life-threatening complications such as acute leukemia or myelofibrosis, a debilitating condition characterized by extensive scarring in the bone marrow that impedes normal blood cell production.
A critical challenge for clinicians has been the inability to reliably predict which patients will maintain stable disease and which are destined for progression. This uncertainty underscores the pressing need for better prognostic tools. The Wellcome Sanger Institute study embarked on a mission to address this gap, investigating whether specific genetic changes could serve as reliable indicators of a patient’s risk for disease progression. Furthermore, the research aimed to rigorously examine whether individuals who lack the common JAK2, CALR, or MPL mutations truly have a bona fide blood cancer or a condition that mimics it.
To achieve this, the research team meticulously followed a cohort of 30 patients diagnosed with chronic blood cancers, predominantly MPNs. The study’s depth was unparalleled, combining whole-genome sequencing—a comprehensive analysis of an individual’s entire DNA—with an exhaustive array of clinical information. This included nearly 8,000 blood test results, detailed treatment records, and extensive disease progression data. Over the course of the study, more than 450 samples were collected and subjected to repeated genomic testing, providing a dynamic molecular snapshot of the disease’s evolution. Critically, some patients were monitored through routine clinical care for an extraordinary duration, extending up to 25 years, providing an invaluable longitudinal perspective rarely achieved in medical research.
Constructing Genetic ‘Family Trees’ of Blood Cells
The unprecedented long-term follow-up established a vital bridge between cutting-edge genomic research conducted at the Wellcome Sanger Institute and routine patient care provided at Cambridge University Hospitals NHS Foundation Trust. This synergistic approach allowed scientists to observe, in real-time, how populations of blood cells changed and diversified over extended periods, offering an expansive and nuanced understanding of cancer evolution within a living system.
Utilizing DNA extracted from blood cells, researchers ingeniously constructed genetic ‘family trees’ for individual patients. These intricate reconstructions served as molecular genealogies, enabling the scientists to trace the ancestral origins of specific cancer clones—groups of genetically identical cells that had accumulated mutations and subsequently contributed to the observed disease progression. By mapping these clonal relationships, the team gained profound insights into the hierarchical development of cancer and the emergence of new, potentially more aggressive cell lines.
The sophisticated analysis unveiled distinct and highly informative patterns of evolutionary change among patients with MPNs. Individuals whose disease remained clinically stable over many years tended to exhibit genetically ‘steady’ blood cell populations, acquiring few, if any, additional mutations. Their clonal architecture remained largely quiescent, reflecting a benign or indolent course. In stark contrast, patients whose disease progressed showed a clear pattern of developing new and diverse DNA changes over time. These emerging mutations often conferred selective advantages to certain cell clones, driving their expansion and contributing to the clinical worsening of the disease.
These findings carry profound implications, strongly suggesting that the propensity for progression in chronic blood cancers may be biologically ‘encoded’ within the patient’s genome years—even decades—before their condition visibly deteriorates or before standard clinical tests reveal a major shift. Mutations specifically linked to future progression may be detectable long before symptoms worsen, offering a critical window for intervention.
Re-evaluating Diagnoses: When Aging Mimics Cancer
Beyond predicting progression, the study also cast a critical eye on patients who lacked the hallmark mutations in JAK2, CALR, or MPL. This subgroup represents a diagnostic conundrum, as their conditions are often characterized by features that overlap with MPNs, yet without the definitive genetic markers.
The researchers reconstructed genetic ‘family trees’ from approximately 200 blood cell genomes belonging to these specific patients. What they discovered was striking: instead of identifying patterns typical of cancer—such as the expansion of a dominant, mutated clone—the scientists observed genetic changes that were far more consistent with normal biological aging. This phenomenon, known as clonal hematopoiesis of indeterminate potential (CHIP), involves the age-related accumulation of somatic mutations in blood stem cells, which can lead to a slight increase in blood cell counts but typically does not progress to overt cancer.
This groundbreaking finding directly challenges the long-held assumption that everyone presenting with certain unusual bone marrow features, even in the absence of canonical MPN mutations, necessarily has a true blood cancer. The study posits that some individuals currently categorized within this disease spectrum may, in fact, possess biological characteristics that are fundamentally different from genuine MPNs, their bone marrow changes being more a reflection of benign age-related processes rather than malignant transformation.
The results necessitate a fundamental reconsideration of how these patients are diagnosed and managed in clinical practice. The distinction is not merely academic; misdiagnosis can lead to significant patient anxiety, unnecessary invasive procedures, and potentially harmful treatments like chemotherapy. The study’s conclusions strongly support new guidelines recently issued by the British Society for Haematology (BSH) for investigating patients without JAK2, CALR, or MPL mutations. These guidelines recommend that some patients with high platelet counts (thrombocytosis) but without clear genetic evidence of cancer should initially be described as having "thrombocytosis without JAK2, CALR or MPL mutations," rather than being immediately labeled with a definitive blood cancer diagnosis. This more cautious approach ensures that patients receive appropriate monitoring without the psychological and physical burden of a potentially inaccurate cancer diagnosis.
Paving the Way for Regular Genomic Monitoring
The comprehensive study profoundly highlights the numerous potential clinical benefits that could arise from integrating genomic information more routinely into cancer care. Genetic testing, as demonstrated by this research, holds the key to distinguishing between stable, indolent disease and cancers that are poised for aggressive progression. It can help clinicians refine uncertain diagnoses, provide greater clarity for patients, and ultimately guide the development of more precise and personalized treatment strategies.
Looking ahead, the vision of regular genomic tests becoming a standard component of patient care is increasingly within reach. Such routine monitoring could empower clinicians to identify high-risk patients years before their disease visibly worsens. This early detection would create unprecedented opportunities to intervene proactively, potentially slowing or preventing progression, while simultaneously allowing for the judicious avoidance of unnecessary or aggressive treatments for individuals whose blood changes may be benign or non-cancerous. This personalized approach promises to optimize patient outcomes, reduce treatment-related side effects, and alleviate the emotional burden associated with chronic illness.
Dr. Daniel Leongamornlert, the first author of the study at the Wellcome Sanger Institute, emphasized the significance of their longitudinal approach: "We followed patients with myeloproliferative neoplasms over many years and leveraged genome sequencing alongside detailed clinical history to meticulously trace how blood cell populations changed over time. By reconstructing the ancestry of cells, we were able to discern starkly different evolutionary patterns between patients who maintained stable disease compared to those who experienced progression. This insight is crucial for understanding the natural history of these cancers."
Dr. Dani Skirrow, Research Information Manager at Cancer Research UK, a key funder of the study, highlighted the broader implications: "We are currently experiencing a golden age of research where technological advancements enable us to rapidly read DNA and pinpoint the errors in the genetic code that drive cancer. Through collaborative efforts, our researchers have analyzed vast amounts of DNA to construct a detailed picture of how certain blood cancers initiate, grow, and behave. This has revealed changes that could potentially allow us to predict cancer progression years in advance. This type of foundational discovery research is absolutely essential to enhance how we monitor individuals at risk of blood cancer and to develop superior methods for prevention, detection, and treatment, ultimately helping people lead longer, healthier lives."
Dr. Jyoti Nangalia, senior author at the Wellcome Sanger Institute and an Honorary Consultant Haematologist at Cambridge University Hospitals NHS Foundation Trust, provided a clinical perspective on the study’s impact: "These are patients we have had the privilege of caring for and following in our clinic for over 15 years. It has historically been incredibly challenging to predict how their cancers might evolve over time. By seamlessly combining long-term clinical care with regular genomic analysis, we have gained the remarkable ability to observe how the genetic code of their disease evolves even before clinical changes become apparent. The distinct patterns we have uncovered will undoubtedly assist doctors in developing more effective monitoring strategies, refining diagnostic accuracy, and ultimately leading to significantly improved patient outcomes in the long run."
A Patient’s Decades-Long Journey: A Testament to the Need for Progress
The human impact of chronic blood cancers is powerfully illustrated by the experience of Alan Everitt, 77, who has received continuous care at Cambridge University Hospitals NHS Foundation Trust for more than three decades. Mr. Everitt was initially diagnosed in 1992 with essential thrombocythemia (ET), a rare form of MPN characterized by the body’s overproduction of platelets, the blood cells critical for clotting. Over time, his condition progressed to myelofibrosis, a more aggressive and debilitating form of MPN that leads to the development of scar tissue within the bone marrow, severely impairing its ability to produce healthy blood cells. In addition to his blood cancer, Mr. Everitt has also grappled with recurrent skin cancers, highlighting the complex and often multi-faceted challenges faced by patients with chronic diseases.
Alan Everitt, from Hardwick, Cambridgeshire, shared his perspective: "It’s been incredibly reassuring to be cared for over so many years by both the hematology and plastic surgery teams at Addenbrooke’s Hospital in Cambridge. I have always felt incredibly well supported and I am deeply grateful for the exceptional care and clear feedback at every step of my journey. Living with a blood cancer for such a long time has presented many challenges, and I sincerely hope that my participation in this research will make a tangible difference for future patients whose cancer is likely to progress over time, much as mine has. Knowing that my experience can contribute to earlier detection and better management for others brings a great deal of comfort."
This research, supported in part by Wellcome and Cancer Research UK, stands as a testament to the power of long-term patient engagement and advanced genomic science. It not only offers a deeper scientific understanding of chronic blood cancers but also promises to translate directly into more accurate diagnoses, personalized monitoring, and earlier, more effective interventions, thereby transforming the lives of countless patients navigating these challenging diseases.
